HCW Biologics Inc. (HCWB)
Automate Your Wheel Strategy on HCWB
With Tiblio's Option Bot, you can configure your own wheel strategy including HCWB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HCWB
- Rev/Share 0.4679
- Book/Share -0.0292
- PB -131.8678
- Debt/Equity -123.5512
- CurrentRatio 0.1079
- ROIC -1.4473
- MktCap 8283687.0
- FreeCF/Share -7.1389
- PFCF -0.6518
- PE -0.318
- Debt/Assets 0.2221
- DivYield 0
- ROE 3.4005
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
HCW Biologics to Participate in the 2025 Maxim Growth Summit
Published: October 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIRAMAR, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, is pleased to announce its participation in the upcoming 2025 Maxim Growth Summit, taking place from October 22nd to 23rd at The Hard Rock Hotel NYC. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the latest trends and advancements across several industries.
Read More
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
Published: September 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Watch the "What This Means" video here
Read More
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
Published: September 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Wugen closed a $115 million equity financing led by Fidelity Management & Research Company HCW Biologics holds a minority equity interest in Wugen MIRAMAR, Fla., Sept. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, congratulates Wugen, Inc. (“Wugen”) on its recently announced $115 million equity financing led by Fidelity Management & Research Company, with participation from RiverVest Venture Partners, Lightchain Capital, Abingworth, ICG, LYZZ Capital, Tybourne Capital Management, Aisling …
Read More
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2025.
Read More
About HCW Biologics Inc. (HCWB)
- IPO Date 2021-07-20
- Website https://www.hcwbiologics.com
- Industry Biotechnology
- CEO Hing C. Wong
- Employees 36